Expression analysis in plasma sample from KRAS G12C–mutant patients monitoring during treatment with KRAS G12C inhibitors

ABSTRACT: Follow-up at baseline, 3 days, 6 weeks after the treatment of KRAS G12C mutant patients treated with KRAS G12C inhibitors in blood

ORGANISM(S): Homo sapiens

PROVIDER: GSE320266 | GEO | 2026/02/28

REPOSITORIES: GEO